How a Supreme Court fight over fish oil could raise your prescription drug costs

NPR reports that the Supreme Court is hearing arguments in Hikma v. Amarin, a patent dispute over a prescription fish oil medication that could significantly affect generic drug market dynamics and potentially raise costs for patients. The case centers on how pharmaceutical patent protections apply to generic competitors, with implications for the broader generics industry's ability to bring lower-cost alternatives to market. Independent coverage from endpoints.news, KUOW, and CNN confirms the case is receiving significant industry attention this week, with CNN noting it's part of a broader slate of cases where major businesses are seeking favorable rulings from the conservative majority. The NPR article demonstrates solid journalistic standards with a named, experienced health reporter, though the description provided lacks specific details about the legal arguments at stake, the particular patent question being litigated, or named sources commenting on expected outcomes—elements that would strengthen the reporting depth.